Importer of Controlled Substances; Notice of Application, 14838-14839 [E8-5523]
Download as PDF
<![CDATA[
14838
Federal Register / Vol. 73, No. 54 / Wednesday, March 19, 2008 / Notices
Mixed Natural and Cultural Site (1)
Papahanaumokuakea Marine National
Monument, Hawaii
Natural Sites (4)
Fagatele Bay National Marine
Sanctuary, American Samoa
Okefenokee National Wildlife Refuge,
Georgia
Petrified Forest National Park, Arizona
White Sands National Monument, New
Mexico
(Authority: 16 U.S.C. 470 a–1, a–2, d; 36 CFR
73)
Dated: March 6, 2008.
Lyle Laverty,
Assistant Secretary for Fish and Wildlife and
Parks.
[FR Doc. E8–5499 Filed 3–18–08; 8:45 am]
BILLING CODE 4312–52–P
DEPARTMENT OF THE INTERIOR
Office of Surface Mining Reclamation
and Enforcement
Notice of Proposed Information
Collection for 1029–0054
Office of Surface Mining
Reclamation and Enforcement.
ACTION: Notice and request for
comments.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995, the
Office of Surface Mining Reclamation
and Enforcement (OSM) is announcing
its intention to request renewed
authority for the collection of
information relating to 30 CFR 872,
Abandoned mine reclamation funds.
DATES: Comments on the proposed
information collection must be received
by May 19, 2008, to be assured of
consideration.
ADDRESSES: Comments may be mailed to
John A. Trelease, Office of Surface
Mining Reclamation and Enforcement,
1951 Constitution Ave., NW, Room 202–
SIB, Washington, DC 20240. Comments
may also be submitted electronically to
jtrelease@osmre.gov.
FOR FURTHER INFORMATION CONTACT: To
receive a copy of the information
collection request contact John A.
Trelease at (202) 208–2783. You may
also review the collection request at
https://www.reginfo.gov/public/do/
PRAMain.
SUPPLEMENTARY INFORMATION: The Office
of Management and Budget (OMB)
regulations at 5 CFR 1320, which
implement provisions of the Paperwork
Reduction Act of 1995 (Pub. L. 104–13),
jlentini on PROD1PC65 with NOTICES
SUMMARY:
VerDate Aug<31>2005
16:50 Mar 18, 2008
Jkt 214001
require that interested members of the
public and affected agencies have an
opportunity to comment on information
collection and recordkeeping activities
[see 5 CFR 1320.8(d)]. This notice
identifies the information collection that
OSM will be submitting to OMB for
approval. This collection is contained in
30 CFR 872, Abandoned mine
reclamation funds. OSM will request a
3-year term of approval for each
information collection activity.
Comments are invited on: (1) The
need for the collection of information
for the performance of the functions of
the agency; (2) the accuracy of the
agency’s burden estimates; (3) ways to
enhance the quality, utility and clarity
of the information collection; and (4)
ways to minimize the information
collection burden on respondents, such
as use of automated means of collection
of the information. A summary of the
public comments will accompany
OSM’s submission of the information
collection request to OMB.
The following information is provided
for the information collection: (1) Title
of the information collection; (2) OMB
control number; (3) summary of the
information collection activity; and (4)
frequency of collection, description of
the respondents, estimated total annual
responses, and the total annual
reporting and recordkeeping burden for
the collection of information.
Title: Abandoned mine reclamation
funds, 30 CFR 872.
OMB Control Number: 1029–0054.
Summary: 30 CFR 872 establishes a
procedure whereby States and Indian
tribes submit written statements
announcing the State/Tribe’s decision
not to submit reclamation plans, and
therefore, will not be granted AML
funds.
Bureau Form Number: None.
Frequency of Collection: Once.
Description of Respondents: State and
Tribal abandoned mine land
reclamation agencies.
Total Annual Responses: 1.
Total Annual Burden Hours: 1.
Dated: March 10, 2008.
John R. Craynon,
Chief, Division of Regulatory Support.
[FR Doc. E8–5389 Filed 3–18–08; 8:45 am]
BILLING CODE 4310–05–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
that on February 15, 2008, Lipomed,
Inc., One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
E:\FR\FM\19MRN1.SGM
19MRN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
14839
Federal Register / Vol. 73, No. 54 / Wednesday, March 19, 2008 / Notices
Schedule
Drug
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Sufentanil (9740) ..........................
DEPARTMENT OF JUSTICE
II
II
II
II
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
jlentini on PROD1PC65 with NOTICES
The company plans to import
analytical reference standards for
distribution to its customers for research
purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than April 18, 2008.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–5523 Filed 3–18–08; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
16:50 Mar 18, 2008
Jkt 214001
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
February 14, 2008, Roche Diagnostics
Operations, Inc., Attn: Regulatory
Compliance, 9115 Hague Road,
Indianapolis, Indiana 46250, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule I and II:
Lysergic acid diethylamide (7315)
Alphamethadol (9605) ..................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
Fmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
I
I
I
II
II
II
II
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
February 29, 2008, AllTech Associates
Inc., 2051 Waukegan Road, Deerfield,
Illinois 60015, made application to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
The company plans to import the
listed controlled substances for the
manufacture of diagnostic products for
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than April 18, 2008.
This procedure is to be conducted
simultaneously with and independent
Frm 00071
Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–5524 Filed 3–18–08; 8:45 am]
Schedule
Drug
PO 00000
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Sfmt 4703
Drug
Cocaine (9041) .............................
Codeine (9050) .............................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Schedule
II
II
II
II
II
II
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
E:\FR\FM\19MRN1.SGM
19MRN1
]]>Agencies
[Federal Register Volume 73, Number 54 (Wednesday, March 19, 2008)]
[Notices]
[Pages 14838-14839]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-5523]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this
is notice that on February 15, 2008, Lipomed, Inc., One Broadway,
Cambridge, Massachusetts 02142, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
Methaqualone (2565)........................ I
Gamma Hydroxybutyric Acid (2010)........... I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Acetyldihydrocodeine (9051)................ I
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Tilidine (9750)............................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
[[Page 14839]]
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Fentanyl (9801)............................ II
Sufentanil (9740).......................... II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may file
comments or objections to the issuance of the proposed registration and
may, at the same time, file a written request for a hearing on such
application pursuant to 21 CFR 1301.43 and in such form as prescribed
by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be filed no later than April 18, 2008.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745), all applicants for
registration to import a basic class of any controlled substances in
schedule I or II are and will continue to be required to demonstrate to
the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration
pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b),
(c), (d), (e) and (f) are satisfied.
Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-5523 Filed 3-18-08; 8:45 am]
BILLING CODE 4410-09-P
